BMJ Case Reports

Acute neurological Behçet’s disease complicated by a syndrome of inappropriate secretion of antidiuretic hormone

We report a rare case of acute neurological Behçet’s disease (neuro-BD) diagnosed concurrently with systemic Behçet’s disease ...
Nasdaq

Biological Efficacy Demonstrated in a Phase 2 Clinical Trial of SGX945 for the treatment of Behçet's Disease

PRINCETON, N.J., July 31, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Nasdaq

Soligenix Reports Promising Phase 2a Results For SGX945 In Behçet's Disease

(RTTNews) - Shares of Soligenix Inc. (SNGX) are up more than 20% at $1.50 in premarket hours, following encouraging results from its Phase 2a proof of concept study of SGX945 in the treatment of ...
Morningstar

Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)

PRINCETON, N.J., Dec. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...
Morningstar

Soligenix Shares Surge on FDA Orphan Designation in Behcet's

Soligenix shares surged more than 50% in early trading Monday after the late-stage biopharmaceutical company won U.S. Food and Drug Administration orphan-drug designation for the active ingredient in ...
KTLA

FDA Grants Soligenix Orphan Drug Designation for the Treatment of Behçet's Disease after Reviewing Recent Phase 2 Clinical Study Results

PRINCETON, N.J., Aug. 18, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to ...